These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23035874)

  • 41. The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.
    Jost P; Peschel C; Ruland J
    Curr Drug Targets; 2006 Oct; 7(10):1335-40. PubMed ID: 17073595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of NF-κB signaling by caspases and MALT1 paracaspase.
    Staal J; Bekaert T; Beyaert R
    Cell Res; 2011 Jan; 21(1):40-54. PubMed ID: 21119681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.
    Oeckinghaus A; Wegener E; Welteke V; Ferch U; Arslan SC; Ruland J; Scheidereit C; Krappmann D
    EMBO J; 2007 Nov; 26(22):4634-45. PubMed ID: 17948050
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.
    Zhang YY; Peng J; Luo XJ
    Biochem Pharmacol; 2022 Apr; 198():114977. PubMed ID: 35218741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB.
    Garrison JB; Samuel T; Reed JC
    Oncogene; 2009 Apr; 28(13):1584-93. PubMed ID: 19234489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
    Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
    FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
    Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of protein kinase C theta, Bcl10, or Malt1 selectively impairs proliferation and NF-kappa B activation in the CD4+ T cell subset.
    Kingeter LM; Schaefer BC
    J Immunol; 2008 Nov; 181(9):6244-54. PubMed ID: 18941215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells.
    Shinohara H; Maeda S; Watarai H; Kurosaki T
    J Exp Med; 2007 Dec; 204(13):3285-93. PubMed ID: 18086859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1.
    Thome M; Tschopp J
    Trends Immunol; 2003 Aug; 24(8):419-24. PubMed ID: 12909454
    [No Abstract]   [Full Text] [Related]  

  • 51. The proteolytic activity of the paracaspase MALT1 is key in T cell activation.
    Rebeaud F; Hailfinger S; Posevitz-Fejfar A; Tapernoux M; Moser R; Rueda D; Gaide O; Guzzardi M; Iancu EM; Rufer N; Fasel N; Thome M
    Nat Immunol; 2008 Mar; 9(3):272-81. PubMed ID: 18264101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
    Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
    Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface.
    Cabalzar K; Pelzer C; Wolf A; Lenz G; Iwaszkiewicz J; Zoete V; Hailfinger S; Thome M
    PLoS One; 2013; 8(8):e72051. PubMed ID: 23977204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1.
    Staal J; Driege Y; Bekaert T; Demeyer A; Muyllaert D; Van Damme P; Gevaert K; Beyaert R
    EMBO J; 2011 May; 30(9):1742-52. PubMed ID: 21448133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A
    De Bruyne M; Hoste L; Bogaert DJ; Van den Bossche L; Tavernier SJ; Parthoens E; Migaud M; Konopnicki D; Yombi JC; Lambrecht BN; van Daele S; Alves de Medeiros AK; Brochez L; Beyaert R; De Baere E; Puel A; Casanova JL; Goffard JC; Savvides SN; Haerynck F; Staal J; Dullaers M
    Front Immunol; 2018; 9():2366. PubMed ID: 30429846
    [No Abstract]   [Full Text] [Related]  

  • 56. Structural insights into the assembly of CARMA1 and BCL10.
    Li S; Yang X; Shao J; Shen Y
    PLoS One; 2012; 7(8):e42775. PubMed ID: 22880103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.
    Varfolomeev E; Wayson SM; Dixit VM; Fairbrother WJ; Vucic D
    J Biol Chem; 2006 Sep; 281(39):29022-9. PubMed ID: 16891304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.
    McAllister-Lucas LM; Jin X; Gu S; Siu K; McDonnell S; Ruland J; Delekta PC; Van Beek M; Lucas PC
    J Biol Chem; 2010 Aug; 285(34):25880-4. PubMed ID: 20605784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.
    Noels H; Somers R; Liu H; Ye H; Du MQ; De Wolf-Peeters C; Marynen P; Baens M
    PLoS One; 2009; 4(3):e4822. PubMed ID: 19279678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defining the combinatorial space of PKC::CARD-CC signal transduction nodes.
    Staal J; Driege Y; Haegman M; Kreike M; Iliaki S; Vanneste D; Lork M; Afonina IS; Braun H; Beyaert R
    FEBS J; 2021 Mar; 288(5):1630-1647. PubMed ID: 32790937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.